Native receptor-targeted chemogenetics enables cell-type-specific inhibition of endogenous receptors in freely moving mice
The study develops native receptor-targeted chemogenetics (NARCH), combining receptor engineering and allosteric ligand design to reversibly and temporally inhibit endogenous neurotransmitter receptor signaling in specific cell types in freely moving mice. Using this approach to target metabotropic glutamate receptor 1 (mGlu1), the authors show that mGlu1 signaling in cerebellar Purkinje cells is required to stabilize motor learning across training sessions. The paper’s explicit caveat is that it focuses on a demonstration in one receptor system and one neural substrate rather than a broad survey across receptors or behaviors, and it notes a patent application for the compounds and strategy. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
1,320 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00